Non hepatitis jaundice - adverse reaction to rifampicin
| Autor: | Ruxandra Jurac, Rodica Potre Oncu, Ruxandra Laza, Alexandru Crişan |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Hepatitis
medicine.medical_specialty Pathology Bilirubin business.industry Liver cell Context (language use) Jaundice medicine.disease Gastroenterology chemistry.chemical_compound Infectious Diseases chemistry Internal medicine Poster Presentation medicine Hyperuricemia medicine.symptom business Adverse effect Rifampicin medicine.drug |
| Zdroj: | BMC Infectious Diseases |
| ISSN: | 1471-2334 |
| DOI: | 10.1186/1471-2334-14-s7-p48 |
| Popis: | Case report The patient to be presented illustrates relapse of TB infection, in the context of significant comorbidities: chronic renal failure, uremic stage, in chronic hemodialysis program; primary hyperuricemia with urate nephropathy; stage II arterial hypertension with very high cardiovascular risk. In the absence of clinical, definite biological and morphological criteria, the diagnosis of drug hepatopathy relies predominantly on causal relationship between the drug administration and the occurrence of the therapeutic accident. Non-hepatitis jaundice (liver tests normal) occurred after 2 weeks of daily tuberculosis treatment, suggesting the involvement of rifampicin in the conjugation of bilirubin and conjugated bilirubin excretion in the bile. The peculiarity of the case: In the patient presented, the fundamental mechanism behind the cholestatic syndrome consisted of: compromising the active transport of bilirubin through the liver cell, without being present the reflux of bile constituents (e.g., bile acids) in the circulation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink